Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

Live Vital vs Jyra Health

Two GLP-1 deals, scored on the same six factors. Live Vital lands a Value Score of 88, Jyra Health a 85. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

Live Vital

#13 · Grade A · Great Deal

Est. first month

$99/mo

Save ~93% vs brand-name
Get this deal Full Live Vital review →
VS

Jyra Health

#31 · Grade A- · Great Deal

Est. first month

From $99/mo (starting dose, plus a separate fee, compounded)

Save ~93% vs brand-name
Get this deal Full Jyra Health review →

The verdict

Better value: Live Vital

Live Vital takes it on Value Score, 88 to 85 an est. $99/mo first month, with no teaser step-up baked in. Jyra Health isn't out of it: Shoppers who want budget shoppers wanting very low-cost compounded semaglutide or tirzepatide in any state.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealLive VitalJyra Health
Value Score88 (A)85 (A-)
Est. first month$99/moFrom $99/mo (starting dose, plus a separate fee, compounded)
Save vs brand-name~93%~93%
Semaglutide$99/moFrom $99/mo (starting dose, plus a separate fee, compounded)
Tirzepatide$183/moFrom $133/mo (starting dose, promotional rate, compounded)
Both moleculesYesYes
PricingFlat — no step-upWatch
CoverageAll 50 statesAll 50 states

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

94
Lowest Real Price
90
Live Vital: 94. Jyra Health: 90.
84
No Teaser-Rate Bait
64
Live Vital: 84. Jyra Health: 64.
98
Nationwide Availability
96
Live Vital: 98. Jyra Health: 96.
90
Both Molecules
92
Live Vital: 90. Jyra Health: 92.
82
Easy Cancellation
95
Live Vital: 82. Jyra Health: 95.
70
Reputation
73
Live Vital: 70. Jyra Health: 73.

Live Vital

$99 flat semaglutide in all 50 states — a strong sema-first deal, with tirzepatide available at $183.

Why it's a deal

  • $99 flat semaglutide — bottom-tier pricing
  • Available in all 50 states
  • Both molecules offered

The fine print

  • Tirzepatide ($183) is pricier than the cheapest rivals
  • Not LegitScript-certified; newer operator

Jyra Health

Jyra Health is an online weight-loss and longevity telehealth clinic offering compounded GLP-1 — semaglutide from $99/mo and tirzepatide from $133/mo (limited time) — prescribed by board-certified providers…

Why it's a deal

  • Among the lowest compounded pricing — semaglutide from $99/mo and tirzepatide from $133/mo, with no membership and no hidden fees
  • Board-certified providers in all 50 states; no insurance required and free express delivery
  • Offers both compounded semaglutide and tirzepatide, plus a longevity track
  • Full legal suite published (Privacy, Terms, HIPAA, Refunds & Cancellations)

The fine print

  • The $133/mo tirzepatide price is flagged 'limited time' — verify current pricing before enrolling
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Zepbound, Ozempic, or Mounjaro
  • Displays a self-hosted LegitScript badge but no verifiable seal or listing
  • Compounding pharmacy not named; appears to be a newer, smaller clinic (~300 patients/month)
Get the Live Vital deal Get the Jyra Health deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores Live Vital is ranked on the Live Vital alternatives ranking, and the same list for the other side is on alternatives to Jyra Health.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.